Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism

Jianguang Chen, Warren Fiskus, Kelly Eaton, Pravina Fernandez, Yongchao Wang, Rekha Rao, Pearl Lee, Rajeshree Joshi, Yonghua Yang, Ravindra Bharat Kolhe, Ramesh Balusu, Prasanthi Chappa, Kavita Natrajan, Anand Jillella, Peter Atadja, Kapil N. Bhalla

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Pan-histone deacetylase inhibitors, for example, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL). However, the molecular basis of this activity remains unclear. HDAC7, a class IIA histone deacetylase (HDAC), is overexpressed in thymocytes, where it represses expression of the proapoptotic nuclear orphan receptor Nur77. Here, we demonstrate that treatment with panobinostat rapidly inhibits the in vitro and intracellular activity, as well as the mRNA and protein levels of HDAC7, and induces expression and translocation of Nur77 to the mitochondria. There, Nur77 converts death resistance protein Bcl-2 into a killer protein, promoting cell death of cultured and patient-derived human CTCL cells. Treatment with panobinostat improved survival of athymic nude mice implanted with human CTCL cells. Ectopic expression of Nur77 induced apoptosis and sensitized HH cells to panobinostat, whereas combined knockdown of Nur77 and its family member Nor1 was necessary to inhibit panobinostat-induced apoptosis of CTCL cells. Cotreatment with the Bcl-2/Bcl-xL antagonist ABT-737 decreased resistance and synergistically induced apoptosis of human CTCL cells. These findings mechanistically implicate HDAC7 and Nur77 in sensitizing human CTCL cells to panobinostat as well as suggest that cotreatment with an anti-Bcl-2 agent would augment the anti-CTCL activity of panobinostat.

Original languageEnglish (US)
Pages (from-to)4038-4048
Number of pages11
JournalBlood
Volume113
Issue number17
DOIs
StatePublished - Nov 17 2009

Fingerprint

Cutaneous T-Cell Lymphoma
T-cells
Apoptosis
Nude Mice
Nuclear Receptor Subfamily 4, Group A, Member 1
Proteins
Mitochondria
Histone Deacetylase Inhibitors
Histone Deacetylases
panobinostat
Cell death
Thymocytes
Cell Death
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chen, J., Fiskus, W., Eaton, K., Fernandez, P., Wang, Y., Rao, R., ... Bhalla, K. N. (2009). Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood, 113(17), 4038-4048. https://doi.org/10.1182/blood-2008-08-176024

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. / Chen, Jianguang; Fiskus, Warren; Eaton, Kelly; Fernandez, Pravina; Wang, Yongchao; Rao, Rekha; Lee, Pearl; Joshi, Rajeshree; Yang, Yonghua; Kolhe, Ravindra Bharat; Balusu, Ramesh; Chappa, Prasanthi; Natrajan, Kavita; Jillella, Anand; Atadja, Peter; Bhalla, Kapil N.

In: Blood, Vol. 113, No. 17, 17.11.2009, p. 4038-4048.

Research output: Contribution to journalArticle

Chen, J, Fiskus, W, Eaton, K, Fernandez, P, Wang, Y, Rao, R, Lee, P, Joshi, R, Yang, Y, Kolhe, RB, Balusu, R, Chappa, P, Natrajan, K, Jillella, A, Atadja, P & Bhalla, KN 2009, 'Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism', Blood, vol. 113, no. 17, pp. 4038-4048. https://doi.org/10.1182/blood-2008-08-176024
Chen, Jianguang ; Fiskus, Warren ; Eaton, Kelly ; Fernandez, Pravina ; Wang, Yongchao ; Rao, Rekha ; Lee, Pearl ; Joshi, Rajeshree ; Yang, Yonghua ; Kolhe, Ravindra Bharat ; Balusu, Ramesh ; Chappa, Prasanthi ; Natrajan, Kavita ; Jillella, Anand ; Atadja, Peter ; Bhalla, Kapil N. / Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. In: Blood. 2009 ; Vol. 113, No. 17. pp. 4038-4048.
@article{432420b29c8e4fff909f0627942f2ccd,
title = "Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism",
abstract = "Pan-histone deacetylase inhibitors, for example, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL). However, the molecular basis of this activity remains unclear. HDAC7, a class IIA histone deacetylase (HDAC), is overexpressed in thymocytes, where it represses expression of the proapoptotic nuclear orphan receptor Nur77. Here, we demonstrate that treatment with panobinostat rapidly inhibits the in vitro and intracellular activity, as well as the mRNA and protein levels of HDAC7, and induces expression and translocation of Nur77 to the mitochondria. There, Nur77 converts death resistance protein Bcl-2 into a killer protein, promoting cell death of cultured and patient-derived human CTCL cells. Treatment with panobinostat improved survival of athymic nude mice implanted with human CTCL cells. Ectopic expression of Nur77 induced apoptosis and sensitized HH cells to panobinostat, whereas combined knockdown of Nur77 and its family member Nor1 was necessary to inhibit panobinostat-induced apoptosis of CTCL cells. Cotreatment with the Bcl-2/Bcl-xL antagonist ABT-737 decreased resistance and synergistically induced apoptosis of human CTCL cells. These findings mechanistically implicate HDAC7 and Nur77 in sensitizing human CTCL cells to panobinostat as well as suggest that cotreatment with an anti-Bcl-2 agent would augment the anti-CTCL activity of panobinostat.",
author = "Jianguang Chen and Warren Fiskus and Kelly Eaton and Pravina Fernandez and Yongchao Wang and Rekha Rao and Pearl Lee and Rajeshree Joshi and Yonghua Yang and Kolhe, {Ravindra Bharat} and Ramesh Balusu and Prasanthi Chappa and Kavita Natrajan and Anand Jillella and Peter Atadja and Bhalla, {Kapil N.}",
year = "2009",
month = "11",
day = "17",
doi = "10.1182/blood-2008-08-176024",
language = "English (US)",
volume = "113",
pages = "4038--4048",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism

AU - Chen, Jianguang

AU - Fiskus, Warren

AU - Eaton, Kelly

AU - Fernandez, Pravina

AU - Wang, Yongchao

AU - Rao, Rekha

AU - Lee, Pearl

AU - Joshi, Rajeshree

AU - Yang, Yonghua

AU - Kolhe, Ravindra Bharat

AU - Balusu, Ramesh

AU - Chappa, Prasanthi

AU - Natrajan, Kavita

AU - Jillella, Anand

AU - Atadja, Peter

AU - Bhalla, Kapil N.

PY - 2009/11/17

Y1 - 2009/11/17

N2 - Pan-histone deacetylase inhibitors, for example, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL). However, the molecular basis of this activity remains unclear. HDAC7, a class IIA histone deacetylase (HDAC), is overexpressed in thymocytes, where it represses expression of the proapoptotic nuclear orphan receptor Nur77. Here, we demonstrate that treatment with panobinostat rapidly inhibits the in vitro and intracellular activity, as well as the mRNA and protein levels of HDAC7, and induces expression and translocation of Nur77 to the mitochondria. There, Nur77 converts death resistance protein Bcl-2 into a killer protein, promoting cell death of cultured and patient-derived human CTCL cells. Treatment with panobinostat improved survival of athymic nude mice implanted with human CTCL cells. Ectopic expression of Nur77 induced apoptosis and sensitized HH cells to panobinostat, whereas combined knockdown of Nur77 and its family member Nor1 was necessary to inhibit panobinostat-induced apoptosis of CTCL cells. Cotreatment with the Bcl-2/Bcl-xL antagonist ABT-737 decreased resistance and synergistically induced apoptosis of human CTCL cells. These findings mechanistically implicate HDAC7 and Nur77 in sensitizing human CTCL cells to panobinostat as well as suggest that cotreatment with an anti-Bcl-2 agent would augment the anti-CTCL activity of panobinostat.

AB - Pan-histone deacetylase inhibitors, for example, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL). However, the molecular basis of this activity remains unclear. HDAC7, a class IIA histone deacetylase (HDAC), is overexpressed in thymocytes, where it represses expression of the proapoptotic nuclear orphan receptor Nur77. Here, we demonstrate that treatment with panobinostat rapidly inhibits the in vitro and intracellular activity, as well as the mRNA and protein levels of HDAC7, and induces expression and translocation of Nur77 to the mitochondria. There, Nur77 converts death resistance protein Bcl-2 into a killer protein, promoting cell death of cultured and patient-derived human CTCL cells. Treatment with panobinostat improved survival of athymic nude mice implanted with human CTCL cells. Ectopic expression of Nur77 induced apoptosis and sensitized HH cells to panobinostat, whereas combined knockdown of Nur77 and its family member Nor1 was necessary to inhibit panobinostat-induced apoptosis of CTCL cells. Cotreatment with the Bcl-2/Bcl-xL antagonist ABT-737 decreased resistance and synergistically induced apoptosis of human CTCL cells. These findings mechanistically implicate HDAC7 and Nur77 in sensitizing human CTCL cells to panobinostat as well as suggest that cotreatment with an anti-Bcl-2 agent would augment the anti-CTCL activity of panobinostat.

UR - http://www.scopus.com/inward/record.url?scp=65449134812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449134812&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-08-176024

DO - 10.1182/blood-2008-08-176024

M3 - Article

VL - 113

SP - 4038

EP - 4048

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -